Epitalon

What it is

Epitalon is a synthetic tetrapeptide described as an analog related to Epithalamin, a polypeptide extract derived from pineal tissue. They are not the same substance. Studies of Epithalamin cannot automatically be treated as studies of Epitalon, and the names are frequently blurred online.

What humans actually show

• Human biomarker study: A 2021 study enrolled 75 women ages 40–59 who had worked primarily night shifts. Thirty-five women with age-normal urinary melatonin-metabolite levels formed a control group. The 40 women with reduced levels were randomly divided between sublingual AEDG and placebo for 20 days; the study evaluated circadian-gene expression. This was a narrow mechanistic study, not an insomnia-outcome trial. The limited human evidence comes largely from the research group that originated this peptide program, an important limitation when weighing the result.
• What that does not establish: The study did not test the nominated subcutaneous route and was not a clinical trial showing that Epitalon treats chronic insomnia, reverses aging, lengthens life, or improves patient-important outcomes.
• Safety evidence: FDA says its search did not identify clinical studies assessing the safety of Epitalon-related bulk drug substances in humans and concluded there are no clinical data supporting human safety.

A biomarker result can be a reason for further research. It is not proof of “age reversal.”

FDA and U.S. status

FDA evaluated Epitalon free base and Epitalon acetate for insomnia. Staff concluded the criteria weigh against including either substance on the 503A Bulks List. The briefing says neither is a component of an FDA-approved drug and identifies inconsistent naming, uncertain substance identity, limited effectiveness evidence, and missing safety information.

On July 24, 2026, PCAC voted 7 yes, 4 no, 1 abstain on the free base and 7 yes, 4 no, 1 abstain on the acetate, recommending inclusion for both forms. The committee's recommendation is advisory: it does not approve Epitalon, validate longevity or insomnia claims, or itself place either form on the 503A Bulks List. FDA's final determination remains pending.

Risks and warning limits

FDA says it found no clinical safety data and no studies assessing immunogenicity or aggregation. It also found no evidence for the proposed subcutaneous route. The lack of adverse-event reports is not proof of safety because use and reporting are incomplete.

PepCurrent does not provide dosing, sourcing, or product-selection advice.

What would change this answer

• FDA's written meeting record and final determination after the advisory recommendation
• Independent, preregistered trials with clinical outcomes
• Studies that clearly distinguish Epitalon from Epithalamin and identify the substance form and route

Sources and records

• FDA staff briefing — Epitalon-related bulk drug substances (2026)
• Ivko et al., 2020 — AEDG and human circadian-gene expression (PubMed record)
• FDA meeting page — July 23–24, 2026 PCAC
• FDA voting questions — exact free-base and acetate questions (PDF)
• FDA-linked Day 2 archived broadcast — Epitalon votes
• PubMed review record — Epitalon literature overview (2025)

Educational journalism only; not medical or legal advice. We do not link vendors or publish protocols.